Who Paid My Doc
Jonathan Hines
Internal Medicine Wilmington, NC Medical Doctor
NPI 1619066040 CMS profile 118576
1202 Medical Center Dr, Wilmington, NC 28401
General payments
$1,060
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jonathan Hines of Wilmington, NC is reported in the CMS Open Payments database as having received $1,060 across 55 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 71st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $96 | 5 | |
| 2021 | General | $107 | 8 | |
| 2020 | General | $233 | 17 | |
| 2019 | General | $624 | 25 |
Beside peers
- Jonathan Hines
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Jonathan Hines were reported at $96. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Jonathan Hines | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $624 | $159 | $48–$570 | $163 |
| 2020 | $233 | $119 | $33–$402 | $114 |
| 2021 | $107 | $135 | $37–$521 | $132 |
| 2022 | $0 | $141 | $42–$496 | $149 |
| 2023 | $0 | $149 | $45–$519 | $160 |
| 2024 | $0 | $154 | $47–$537 | $164 |
| 2025 | $96 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 147 drugsPart D claims
9,956
Drug cost
$544,896
Branded share of claims
16.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 90 | $123,790 | |
| Eliquis Apixaban | Brand | 113 | $104,796 | |
| Xarelto Rivaroxaban | Brand | 39 | $43,709 | |
| Farxiga Dapagliflozin Propanediol | Brand | 17 | $23,457 | |
| Mounjaro Tirzepatide | Brand | 16 | $22,287 | |
| Januvia Sitagliptin Phosphate | Brand | 31 | $20,419 | |
| Jardiance Empagliflozin | Brand | 23 | $18,066 | |
| Trulicity Dulaglutide | Brand | 12 | $15,443 | |
| Myrbetriq Mirabegron | Brand | 23 | $10,100 | |
| Atorvastatin Calcium | Generic | 782 | $9,595 |
The 10 drugs with the highest cost, of 147 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 99 billing codesPaid by Medicare
$230,664
Medicare patients
739
Services billed
12,167
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 45% | |
| Diabetes | 41% | |
| Chronic kidney disease | 40% | |
| Ischemic heart disease | 35% | |
| Depression | 32% | |
| Atrial fibrillation | 23% | |
| COPD | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Pcv20 vaccine im 90677 | Office | 89 | 89 | $25,949 |
| Injection, denosumab, 1 mg J0897 | Office | 11 | 900 | $18,562 |
| Vaccine for influenza for injection into muscle 90662 | Office | 80 | 82 | $6,458 |
| Vaccine for tetanus and diphtheria toxoids injection into muscle, patient 7 years or older 90714 | Office | 24 | 24 | $563 |
| Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 | Office | 16 | 16 | $486 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
55 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in North Carolina
Related records
Internal Medicine in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.